Skip to main content
Home > SciBX > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Fat chance for cancer cachexia

    With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies may consider targeting the cause of the wasting disease rather than its symptoms. Two independent academic …

    Published on 8/21/2014
  • Cancer-associated cachexia products in clinical development

    Cover Story: Fat chance for cancer cachexia Table 1. Cancer-associated cachexia products in clinical development. Although two compounds failed in Phase III trials for cancer cachexia, the landscape is still full of…

    Published on 8/21/2014
  • Navigating the new road in psychiatry

    The lack of predictive animal models for neuropsychiatric diseases is arguably the biggest single factor stifling early drug development in the field. To kick-start discovery for diseases such as autism, schizophrenia …

    Published on 8/14/2014
  • Box 1. Once more into the misfoldome

    Cover Story: Dyeing to diagnose preeclampsia Box 1. Once more into the misfoldome. In addition to identifying a method for diagnosing preeclampsia, the report in Science Translational Medicine suggests that the …

    Published on 8/7/2014
  • Dyeing to diagnose preeclampsia

    A Congo red-based urine test that could rapidly confirm a diagnosis of preeclampsia might avoid treatment delays. The method will be tested in an international trial next year and has been licensed by Yale spinout …

    Published on 8/7/2014
  • Fresh air for COPD

    An undisclosed company has picked up an integrin-targeting antibody from UCSF that could address the underlying pathology in COPD by improving airway remodeling via suppression of TGFB1.

    Published on 7/31/2014
  • Box 1: Attributes of the GalNAc-ASGR1 system

    Cover Story: It is an RNA world Box 1. Attributes of the GalNAc-ASGR1 system. · Ligand with nanomolar affinity for receptor · Tissue- or cell type-restricted expression of the receptor · High copy number of …

    Published on 7/24/2014
  • Box 2: Considerations for compelling target and therapeutic validation

    Cover Story: It is an RNA world Box 2. Considerations for compelling target and therapeutic validation. · Empirical validation that the lncRNA target is expressed in the right place at the right time to impact the …

    Published on 7/24/2014
  • It is an RNA world

    RNA-based drugs have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent, turning RNA into the biotech industry's de facto third drug …

    Published on 7/24/2014
  • Table 1: 2014 first-quarter industry activity in RNA therapeutics

    Cover Story: It is an RNA world Table 1. 2014 first-quarter industry activity in RNA therapeutics. Deals involving Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) headline a barrage of activity totaling over $1 billion in…

    Published on 7/24/2014
  • Table 2: Accessible human tissues

    Cover Story: It is an RNA world Table 2. Accessible human tissues. Tissues that are accessible to single-stranded antisense and double-stranded RNAi therapeutics in human patients with exemplary therapeutics and …

    Published on 7/24/2014
  • Table 3: Orphan drug designations

    Cover Story: It is an RNA world Table 3. Orphan drug designations. Companies with RNA therapeutics programs receiving orphan drug designations from the FDA. Source: http://www.fda.gov/; BCIQ: BioCentury Online …

    Published on 7/24/2014
  • Table 4: Delivery platforms

    Cover Story: It is an RNA world Table 4. Delivery platforms. Platforms in clinical development to deliver RNA therapeutics in vivo. Platform Company Program Description Stage Encapsulation platforms Lipid …

    Published on 7/24/2014
  • Fixing mitophagy in Parkinson's disease

    Genentech has pulled back the curtain on its efforts in Parkinson's disease and described a new and potentially disease-modifying target involved in the clearance of damaged mitochondria. The Roche unit now needs to …

    Published on 7/17/2014
  • Going immune on beige fat

    Two independent teams at UCSF and Harvard have found an immune-regulated pathway for beige fat formation and a hormone, METRNL, that activates it. Ember Therapeutics has an option to license the molecule, which could …

    Published on 7/10/2014
  • Figure 1: Pathway for driving beige fat formation

    Cover Story: Going immune on beige fat Figure 1. Pathway for driving beige fat formation. Cold stimulus promotes beige fat formation and thermogenesis, but the pathways involved in such processes were unclear. The …

    Published on 7/10/2014
  • Keys to the CAR

    Although companies, investors and academics are all racing to develop chimeric antigen receptor -- based T cells for cancer, numerous scientific challenges still constrain the technology. The way forward will likely …

    Published on 6/26/2014
  • Figure 1: Building a better T cell

    Cover Story: Keys to the CAR Figure 1. Building a better T cell. Various engineering strategies can be used to design T cells to engage tumor-associated antigens and kill tumor tissue while sparing normal tissue.

    Published on 6/26/2014
  • Figure 2: Receptor expression and engagement of antigen

    Cover Story: Keys to the CAR Figure 2. Receptor expression and engagement of antigen. (I) T cell receptors (TCRs) consist of a heterodimer of a- and b-chains that associate with the g-, d-, e- and z-chains of the CD3…

    Published on 6/26/2014
  • Breaking MYC metabolism

    The metabolic enzyme PRPS2 could represent a tractable way to modulate the notoriously undruggable oncogene MYC. The findings from a UCSF team are licensed to Effector Therapeutics and provide a clue as to how the …

    Published on 6/19/2014
  • Nav-i-gating antibodies for pain

    Nav1.7 entered the scene a decade ago as a pain target with wide-ranging analgesic effects, but it has been difficult to selectively target. Now, a team at Duke has succeeded with an antibody that blocks the channel in …

    Published on 6/12/2014
  • Table 1: Nav1.7 small molecule inhibitors and antibodies

    Cover Story: Nav-i-gating antibodies for pain Table 1. Nav1.7 small molecule inhibitors and antibodies. Specifically blocking the Nav1.7 (SCN9A) voltage-gated sodium channel subtype suppresses pain. At least six …

    Published on 6/12/2014
  • Alas, porphyria

    Treatment of acute porphyrias has long relied on hemin infusions, but the therapy has many drawbacks. A team led by Alnylam has created an siRNA therapeutic that reduces disease symptoms in mice. The company still needs…

    Published on 6/5/2014
  • Personalized medicine gets personal

    Epithelial cancers are the most common malignancies, but immunotherapy development has been stymied because the low mutation frequency of these tumors elicits muted mutation-specific T cell responses. An NCI team has …

    Published on 5/29/2014
  • Ob(nox)ious fibrosis

    Although the most advanced drug for idiopathic pulmonary fibrosis has shown a mortality benefit, the effects are modest and there remains room for improvement. New preclinical findings suggest inhibiting NOX4 could both…

    Published on 5/22/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993